Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test

Journal of Virological Methods

Volumn 187, Issue 2, 2013, Pages 288-293

  Shen, Yong ^a   Gong, Jiaomei ^a   He, Yanxia ^a   Cheng, Guomei ^a   Okunieff, Paul ^b   Li, Xiaofu ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cervical lesion; E6 E7 mRNA; HPV DNA; Human papillomavirus; Liquid based cytology triage

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA;

ADULT; ARTICLE; COLPOSCOPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DNA HYBRIDIZATION; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LOW RISK POPULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RNA HYBRIDIZATION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; REAGENT KITS, DIAGNOSTIC; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 84871411212     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.11.024     Document Type: Article

References (31)

1. Albrechtsen S., Rasmussen S., Thoresen S., Irgens L.M., Iversen O.E. Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ 2008, 337:a1343.
2. Arbyn M., Roelens J., Cuschieri K., Cuzick J., Szarewski A., Ratnam S., Reuschenbach M., Belinson S., Belinson J.L., Monsonego J. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int. J. Cancer 2012.
3. Arbyn M., Simoens C., Goffin F., Noehr B., Bruinsma F. Treatment of cervical cancer precursors: influence of age, completeness of excision and cone depth on therapeutic failure, and on adverse obstetric outcomes. BJOG 2011, 118:1274-1275. author reply 1275-6.
4. Arbyn M., Walker A., Meijer C.J. HPV-based cervical-cancer screening in China. Lancet Oncol. 2010, 11:1112-1113.
5. Benevolo M., Vocaturo A., Caraceni D., French D., Rosini S., Zappacosta R., Terrenato I., Ciccocioppo L., Frega A., Giorgi Rossi P. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J. Clin. Microbiol. 2011, 49:2643-2650.
6. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective, international biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 1995, 87:796-802.
7. Castle P.E., Gage J.C., Wheeler C.M., Schiffman M. The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet. Gynecol. 2011, 118:1222-1229.
8. Dalstein V., Riethmuller D., Pretet J.L., Le Bail Carval K., Sautiere J.L., Carbillet J.P., Kantelip B., Schaal J.P., Mougin C. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer 2003, 106:396-403.
9. Dockter J., Schroder A., Hill C., Guzenski L., Monsonego J., Giachetti C. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol. 2009, 45(Suppl. 1):S55-S61.
10. Hovland S., Muller S., Skomedal H., Mints M., Bergstrom J., Wallin K.L., Karlsen F., Johansson B., Andersson S. E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure. Int. J. Oncol. 2010, 36:1533-1539.
11. Koliopoulos G., Chrelias C., Pappas A., Makridima S., Kountouris E., Alepaki M., Spathis A., Stathopoulou V., Panayiotides I., Panagopoulos P., Karakitsos P., Kassanos D. The diagnostic accuracy of two methods for E6&7 mRNA detection in women with minor cytological abnormalities. Acta Obstet. Gynecol. Scand. 2012, 91:794-801.
12. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006, 367:489-498.
13. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 2004, 78:11451-11460.
14. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527.
15. Ratnam S., Coutlee F., Fontaine D., Bentley J., Escott N., Ghatage P., Gadag V., Holloway G., Bartellas E., Kum N., Giede C., Lear A. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J. Clin. Microbiol. 2010, 48:2779-2785.
16. Ratnam S., Coutlee F., Fontaine D., Bentley J., Escott N., Ghatage P., Gadag V., Holloway G., Bartellas E., Kum N., Giede C., Lear A. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J. Clin. Microbiol. 2011, 49:557-564.
17. Rijkaart D.C., Heideman D.A., Coupe V.M., Brink A.A., Verheijen R.H., Skomedal H., Karlsen F., Morland E., Snijders P.J., Meijer C.J. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J. Clin. Microbiol. 2012, 50:2390-2396.
18. Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., Hingmire S., Malvi S.G., Thorat R., Kothari A., Chinoy R., Kelkar R., Kane S., Desai S., Keskar V.R., Rajeshwarkar R., Panse N., Dinshaw K.A. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 2009, 360:1385-1394.
19. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., Garcia F.A., Moriarty A.T., Waxman A.G., Wilbur D.C., Wentzensen N., Downs L.S., Spitzer M., Moscicki A.B., Franco E.L., Stoler M.H., Schiffman M., Castle P.E., Myers E.R. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 2012, 137:516-542.
20. Sjoborg K.D., Vistad I., Myhr S.S., Svenningsen R., Herzog C., Kloster-Jensen A., Nygard G., Hole S., Tanbo T. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet. Gynecol. Scand. 2007, 86:423-428.
21. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., Raab S., Sherman M., Wilbur D., Wright T., Young N. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119.
22. Sorbye S.W., Arbyn M., Fismen S., Gutteberg T.J., Mortensen E.S. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One 2011, 6:e26022.
23. Sorbye S.W., Fismen S., Gutteberg T., Mortensen E.S. Triage of women with minor cervical lesions: data suggesting a " test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 2010, 5:e12724.
24. Sorbye S.W., Fismen S., Gutteberg T.J., Mortensen E.S. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J. Virol. Methods 2010, 169:219-222.
25. Sotlar K., Stubner A., Diemer D., Menton S., Menton M., Dietz K., Wallwiener D., Kandolf R., Bultmann B. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J. Med. Virol. 2004, 74:107-116.
26. Sun C.A., Liu J.F., Wu D.M., Nieh S., Yu C.P., Chu T.Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int. J. Gynaecol. Obstet. 2002, 76:41-47.
27. Szarewski A., Mesher D., Cadman L., Austin J., Ashdown-Barr L., Ho L., Terry G., Liddle S., Young M., Stoler M., McCarthy J., Wright C., Bergeron C., Soutter W.P., Lyons D., Cuzick J. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study. J. Clin. Microbiol. 2012, 50:1867-1873.
28. Trope A., Sjoborg K., Eskild A., Cuschieri K., Eriksen T., Thoresen S., Steinbakk M., Laurak V., Jonassen C.M., Westerhagen U., Jacobsen M.B., Lie A.K. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J. Clin. Microbiol. 2009, 47:2458-2464.
29. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
30. Waldstrom M., Ornskov D. Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US). Cytopathology 2011.
31. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.